Adolor and GlaxoSmithKline have announced that the FDA has approved Entereg capsules to help patients regain gastrointestinal function earlier following bowel resection surgery.
Subscribe to our email newsletter
Entereg is indicated to accelerate upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Entereg will be available for short-term use in hospitals registered under the Entereg Access Support and Education (EASE) program.
Michael Dougherty, president and CEO of Adolor, said: “Entereg is the first and only product that has demonstrated the ability to address this serious condition, which has negative consequences for patients, and imposes considerable expense on the healthcare system.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.